Tìm theo
Olcegepant
anti migraine agents
Thuốc Gốc
Small Molecule
CAS: 204697-65-4
CTHH: C38H47Br2N9O5
PTK: 869.645
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C38H47Br2N9O5
Phân tử khối
869.645
Monoisotopic mass
867.206690953
InChI
InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)
InChI Key
InChIKey=ITIXDWVDFFXNEG-UHFFFAOYSA-N
IUPAC Name
N-{6-amino-1-oxo-1-[4-(pyridin-4-yl)piperazin-1-yl]hexan-2-yl}-3-(3,5-dibromo-4-hydroxyphenyl)-2-({[4-(2-oxo-1,2,3,4-tetrahydroquinazolin-3-yl)piperidin-1-yl]carbonyl}amino)propanamide
Traditional IUPAC Name
N-{6-amino-1-oxo-1-[4-(pyridin-4-yl)piperazin-1-yl]hexan-2-yl}-3-(3,5-dibromo-4-hydroxyphenyl)-2-{[4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidin-1-yl]carbonylamino}propanamide
SMILES
NCCCCC(NC(=O)C(CC1=CC(Br)=C(O)C(Br)=C1)NC(=O)N1CCC(CC1)N1CC2=CC=CC=C2NC1=O)C(=O)N1CCN(CC1)C1=CC=NC=C1
Độ hòa tan
3.24e-02 g/l
logP
1.62
logS
-4.4
pKa (strongest acidic)
6.75
pKa (Strongest Basic)
10.19
PSA
176.47 Å2
Refractivity
214.28 m3·mol-1
Polarizability
84.05 Å3
Rotatable Bond Count
12
H Bond Acceptor Count
8
H Bond Donor Count
5
Physiological Charge
1
Number of Rings
6
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Olcegepant is a calcitonin gene-related peptide (CGRP) antagonist. In preclinical studies, olcegepant attenuated arterial dilation induced by CGRP or electrical stimulation. In a phase II clinical trial, olcegepant reduced the severity of headache in 60% of migraine sufferers and met secondary endpoints including headache-free rate and rate of sustained response. Only mild-to-moderate transient adverse events were observed, with no adverse cardiovascular symptoms reported. The compound appears to be an effective anti-migraine medication that is well tolerated and does not display the vasoconstrictive effect that precludes the use of triptans and dihydroergotamine in certain patients.
Cơ Chế Tác Dụng : Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. Migraine involves dysfunction of brainstem pathways that normally modulate sensory input. The involvement of calcitonin gene-related peptide (CGRP) in migraine pathology is supported by both clinical and experimental evidence. The release of CGRP and other neuropeptides from trigeminal nerves is thought to mediate neurogeate inflammation within the meninges which contributes to the generation of severe cerebral pain experienced during migraine attack. CGRP antagonists such as olcegepant bind at CGRP receptors, blocking the effect CGRP and thus reducing inflammation.
Chỉ Định : For the treatment of migraine headaches.
Liều Lượng & Cách Dùng : Solution - Intravenous
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB04869
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=3025955
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=3819966
ChemSpider
http://www.chemspider.com/Chemical-Structure.2291583.html
... loading
... loading